- Details
- Ursula Vogl converses with Alicia Morgans about determining optimal therapeutic strategies in treating metastatic hormone-sensitive prostate cancer. Vogl discusses the selection between doublet and triplet therapies, acknowledging that there are no absolute answers. She presents her pro-triplet therapy argument from the European Association of Urology (EAU) 2023 meeting. Referencing key trials suc...
|
- Details
- Jeremie Calais discusses a retrospective analysis of the use of PSMA PET in salvage radiotherapy with Alicia Morgans. The study focused on the application of PSMA PET findings to the treatment of patients with biochemical recurrence after radical prostatectomy, with approximately 4-5 years of follow-up. They discovered that disease presence correlates with negative outcomes and that the number of...
|
- Details
- Tanya Dorff shares her team’s insights on research into CAR T therapy targeting Prostate Stem Cell Antigen (PSCA). Their analysis shows promise in managing advanced castration-resistant prostate cancer. However, this treatment also presents challenges, including the issue of dose escalation due to the occurrence of high-grade cystitis, a complication encountered during the trials. In response, Dor...
|
- Details
- Alicia Morgans and Neal Shore discuss the integration of the newly-approved Lutetium-617 into clinical practice for the treatment of advanced prostate cancer. The conversation revolves around the revolutionary potential of theranostics, where radiopharmaceuticals are linked with antibodies, such as PSMA. They further analyze the VISION trial, which demonstrated survival and quality of life benefit...
|
- Details
- In an interview with Alicia Morgans, Karim Fizazi discusses cohort two of the TALAPRO-2 study. The cohort, which consists of nearly 400 men with DNA repair defects, proves highly insightful for prostate cancer research. Professor Fizazi reveals that the cohort’s results showed a 55% reduction in the risk of progression or death, with patients having BRCA1 and BRCA2 alterations showing particularly...
|
- Details
- Alicia Morgans speaks with Cora Sternberg about precision medicine's transformative impact on prostate cancer treatment. A key topic is the TALAPRO-2 study, which examines the efficacy of the PARP inhibitor talazoparib in combination with enzalutamide in treating metastatic castration-resistant prostate cancer (CRPC). The study's positive findings suggest significant benefits for patients with BRC...
|
- Details
- Daniel George and Alicia Morgans explore the groundbreaking results of the PANTHER study. The study addresses an enduring gap in clinical trials concerning black patients, who are disproportionately affected by prostate cancer. The PANTHER study investigates the effects of a novel combination of hormonal therapies, apalutamide and abiraterone, in castrate-resistant prostate cancer. Intriguingly, t...
|
- Details
- Alicia Morgans interviews Praful Ravi about his abstract presentation concerning PSA nadir within the ICECaP data set. ICECaP, a comprehensive data repository of individual patient data from more than 40 randomized trials conducted in localized prostate cancer, reveals that metastasis-free survival (MFS) is a proven surrogate for overall survival. In their study, Ravi and his team leveraged the IC...
|
- Details
- Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers. Primaril...
|
- Details
- Alicia Morgans engages in a conversation with Bridget Koontz about the NRG-GU-011 (NRG PROMETHEAN) study. This double-blinded, randomized phase II trial focuses on prostate cancer patients with biochemical recurrence and oligometastatic disease, detected via PET scan. The study explores the potential benefits of radiation, specifically SBRT, either alone or combined with Relugolix for six months....
|
